Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03984097
Title A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

multiple myeloma

Therapies

Dexamethasone + Lenalidomide + TAK-079

Bortezomib + Dexamethasone + Lenalidomide + TAK-079

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.